☰

Sven de Vos, Ph.D. - Publications

Affiliations: 
2003 University of California, Los Angeles, Los Angeles, CA 
Area:
Pathology, Oncology
Tree Info Grants Similar researchers PubMed Report error

21 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Filosto S, Vardhanabhuti S, Canales MA, Poire X, Lekakis LJ, de Vos S, Portell CA, Wang Z, To C, Schupp M, Poddar S, Trinh T, Warren CM, Aguilar EG, Budka J, et al. Product attributes of CAR T-cell therapy differentially associate with efficacy and toxicity in second-line large B-cell lymphoma (ZUMA-7). Blood Cancer Discovery. PMID 37983485 DOI: 10.1158/2643-3230.BCD-23-0112  0.326
2022 Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, Chen JM, Roshandell M, Harris CM, Khericha M, Schweppe T, Berent-Maoz B, Gosliner SB, Almaktari A, Ayala Ceja M, ... ... de Vos S, et al. CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Cancer Discovery. PMID 36416874 DOI: 10.1158/2159-8290.CD-22-0964  0.48
2021 Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. The Lancet. Oncology. PMID 34895487 DOI: 10.1016/S1470-2045(21)00591-X  0.319
2021 Ghafouri S, Fenerty K, Schiller G, de Vos S, Eradat H, Timmerman J, Larson S, Mead M. Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience. Clinical Lymphoma, Myeloma & Leukemia. PMID 34389271 DOI: 10.1016/j.clml.2021.07.002  0.308
2017 Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, et al. Targeting BTK with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. PMID 28167659 DOI: 10.1182/blood-2016-10-747345  0.305
2014 de Vos S, Forero-Torres A, Ansell SM, Kahl B, Cheson BD, Bartlett NL, Furman RR, Winter JN, Kaplan H, Timmerman J, Whiting NC, Drachman JG, Advani R. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. Journal of Hematology & Oncology. 7: 44. PMID 24919462 DOI: 10.1186/1756-8722-7-44  0.334
2012 Clark MC, Pang M, Hsu DK, Liu FT, de Vos S, Gascoyne RD, Said J, Baum LG. Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood. 120: 4635-44. PMID 23065155 DOI: 10.1182/Blood-2012-06-438234  0.47
2011 Flinn IW, Schreeder MT, Coutre SE, Leonard J, Wagner-Johnston ND, De Vos S, Boccia RV, Holes L, Peterman S, Miller LL, Yu AS. A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3064. PMID 28022568 DOI: 10.1200/Jco.2011.29.15_Suppl.3064  0.305
2011 Burington B, Yue P, Shi X, Advani R, Lau JT, Tan J, Stinson S, Stinson J, Januario T, de Vos S, Ansell S, Forero-Torres A, Fedorowicz G, Yang TT, Elkins K, et al. CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Science Translational Medicine. 3: 74ra22. PMID 21411738 DOI: 10.1126/scitranslmed.3001620  0.307
2010 Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 115: 2578-85. PMID 19965662 DOI: 10.1182/Blood-2009-08-236471  0.358
2009 de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory SA, Holladay C, Zhang T, Boral AL. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5023-30. PMID 19770386 DOI: 10.1200/JCO.2008.17.7980  0.309
2006 Kaluza V, Rao DS, Said JW, de Vos S. Primary extranodal nasal-type natural killer/T-cell lymphoma of the brain: a case report. Human Pathology. 37: 769-72. PMID 16733220 DOI: 10.1016/J.Humpath.2006.01.032  0.49
2004 Takeuchi S, de Vos S, Takeuchi N, Fermin AC, Grogan TM, Seo H, Said JW, Koeffler HP. Allelic loss during progression of follicular lymphoma. Leukemia Research. 28: 567-9. PMID 15120932 DOI: 10.1016/j.leukres.2003.10.025  0.43
2004 Rummel MJ, de Vos S, Hoelzer D, Koeffler HP, Hofmann WK. Altered apoptosis pathways in mantle cell lymphoma. Leukemia & Lymphoma. 45: 49-54. PMID 15061196  0.406
2003 de Vos S, Krug U, Hofmann WK, Pinkus GS, Swerdlow SH, Wachsman W, Grogan TM, Said JW, Koeffler HP. Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV. Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B. 12: 35-43. PMID 12605034 DOI: 10.1097/00019606-200303000-00005  0.496
2003 de Vos S, Hofmann WK, Grogan TM, Krug U, Schrage M, Miller TP, Braun JG, Wachsman W, Koeffler HP, Said JW. Gene expression profile of serial samples of transformed B-cell lymphomas. Laboratory Investigation; a Journal of Technical Methods and Pathology. 83: 271-85. PMID 12594241 DOI: 10.1097/01.Lab.0000053913.85892.E9  0.498
2001 Hofmann WK, de Vos S, Tsukasaki K, Wachsman W, Pinkus GS, Said JW, Koeffler HP. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood. 98: 787-94. PMID 11468180 DOI: 10.1182/Blood.V98.3.787  0.478
1997 Said JW, Tasaka T, de Vos S, Koeffler HP. Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8 encephalitis in HIV-positive and -negative individuals. Aids (London, England). 11: 1119-22. PMID 9233458 DOI: 10.1097/00002030-199709000-00006  0.438
1997 DePond W, Said JW, Tasaka T, de Vos S, Kahn D, Cesarman E, Knowles DM, Koeffler HP. Kaposi's sarcoma-associated herpesvirus and human herpesvirus 8 (KSHV/HHV8)-associated lymphoma of the bowel. Report of two cases in HIV-positive men with secondary effusion lymphomas. The American Journal of Surgical Pathology. 21: 719-24. PMID 9199651 DOI: 10.1097/00000478-199706000-00013  0.475
1996 Said J, Tasaka T, Takeuchi S, Asou H, de Vos S, Cesarman E, Knowles D, Koeffler H. Primary effusion lymphoma in women: report of two cases of Kaposi's sarcoma herpes virus-associated effusion-based lymphoma in human immunodeficiency virus-negative women Blood. 88: 3124-3128. DOI: 10.1182/blood.V88.8.3124.bloodjournal8883124  0.309
1996 Said W, Chien K, Takeuchi S, Tasaka T, Asou H, Cho S, de Vos S, Cesarman E, Knowles D, Koeffler H. Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells Blood. 87: 4937-4943. DOI: 10.1182/Blood.V87.12.4937.Bloodjournal87124937  0.363
Show low-probability matches.